Ardelyx reports preliminary Q4 2024 net product sales: IBSRELA $54M, XPHOZAH $57M

ARDELYX, INC.

2024-FY EPS reported -$0.17 revenue$333,615,000

IBSRELA net product sales: ~$54M in Q4 2024, ~$158M full year.
XPHOZAH net product sales: ~$57M in Q4 2024, ~$161M full year.
Cash, cash equivalents, and short-term investments: ~$250M as of Dec 31, 2024 (unaudited).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.